SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Rhea-AI Summary

CG Oncology (NASDAQ: CGON) and the Society of Urologic Oncology Clinical Trials Consortium announced the second annual CG‑SUO‑CTC NMIBC Research Fellowship on December 18, 2025. Two investigators will each receive a $50,000 grant to support clinical, translational, or basic research in Non‑Muscle Invasive Bladder Cancer (NMIBC). Applications are due February 27, 2026, 5:00 PM ET. Awarded projects must be presented at the SUO meeting during the American Urological Association annual meeting. Selection is based on research plan quality and available resources.

Key Figures

Fellowship grants $50,000 each Two NMIBC research fellows supported by CG Oncology and SUO-CTC

Number of awardees 2 investigators Second annual NMIBC research fellowship program

Application deadline February 27, 2026 Fellowship applications due by 5:00 PM U.S. Eastern Time

Market Reality Check

$39.03 Last Close

Volume Volume 823,214 vs 20-day average 751,293 indicates slightly elevated trading activity before this fellowship news. normal

Technical Price $37.37 was trading above the 200-day MA of $30.78 and about 18.78% below the 52-week high.

Peers on Argus 1 Up

Biotech peers showed mixed moves pre-news: FOLD up 0.55%, while CELC, TARS, IBRX, and LQDA were down between 0.83% and 2.84%. Momentum scanner only flagged OCUL up 9.26% without news, suggesting no broad sector driver tied to this fellowship announcement.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 05	Clinical data update	Positive	-3.7%	Topline BOND-003 and CORE-008 data showed strong efficacy and tolerability in NMIBC.
Nov 26	Board change & BLA	Positive	-1.5%	New director added and BLA initiation for cretostimogene highlighted commercialization focus.
Nov 25	Conference presentation	Neutral	-1.5%	Announced late-breaking SUO presentations and posters on key NMIBC trials.
Nov 14	Earnings & updates	Positive	+8.6%	Q3 results with strong cash position, BLA initiation, and early Phase 3 completion.
Sep 05	Clinical durability data	Positive	+6.9%	Reported durable 24‑month CR and low progression in BOND‑003 Cohort C NMIBC patients.

Pattern Detected

Recent clinically positive or strategic updates often saw mixed to negative immediate reactions, while broader earnings-plus-clinical updates drew stronger positive moves.

Recent Company History

Over the last six months, CG Oncology has repeatedly highlighted cretostimogene’s potential in high‑risk NMIBC, with strong durability and response data reported on Sep 05 and detailed again on Dec 05. The company advanced toward commercialization, initiating a rolling BLA and completing a Phase 3 trial’s enrollment early, as reported on Nov 14. Board changes and SUO presentation plans in late November reinforced launch and data‑presentation readiness. Today’s NMIBC fellowship news fits this pattern of deepening engagement with the urologic oncology community around the same disease area.

Market Pulse Summary

This announcement formalizes CG Oncology’s collaboration with SUO‑CTC through a second annual NMIBC research fellowship, funding two investigators with $50,000 grants each. It reinforces the company’s focus on non‑muscle invasive bladder cancer, complementing recent clinical data and BLA progress in the same indication. Investors may watch how supported projects align with cretostimogene’s development and whether future updates from these fellows contribute to CGON’s broader clinical and academic footprint.

Key Terms

non-muscle invasive bladder cancer medical

"commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer"

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

NMIBC medical

"development of outstanding clinical cancer research to improve the treatment of NMIBC"

A common form of bladder cancer that stays confined to the bladder’s inner lining or the layer just below it and has not grown into the deeper muscle wall. It matters to investors because it often requires repeated procedures, ongoing surveillance and long-term treatments, creating a sizable and stable market for diagnostics, drugs and medical devices; think of it like a surface-level problem that needs frequent check-ups and follow-up care rather than a one-time fix.

AI-generated analysis. Not financial advice.

• Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC
  
  
• Applications for the fellowship are due on February 27, 2026
  

SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

“There remains a significant unmet need for treating NMIBC, and this fellowship is helping advance research and drive innovation, leading to improvements in patient care. We are fortunate to have a very bright and motivated next generation of urologists entering the field, and this program offers an exceptional opportunity for them to collaborate with mentors and present their work at a prominent forum like AUA as we enter its second year,” said Colin P. N. Dinney, MD, a Professor of Urology at the University of Rochester Medical Center. 

“Partnering with the SUO-CTC on this fellowship reflects our shared dedication to advancing care for patients with urologic cancers,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “By fostering research and collaboration, this program moves us closer to innovations that can truly improve patients’ lives.”

To apply for this fellowship, investigators may be working in basic, translational and clinical research fields, and they must be working in a research environment capable of supporting transformational NMIBC research. All applications are due by Friday, February 27, 2026, at 5:00 PM U.S. Eastern Time. Applications will be evaluated on the quality of the applicant’s proposed research plan and the resources and environment available to the applicant. Two applicants will each receive a Grant of $50,000. The completed project will be presented at the SUO meeting at the American Urological Association (AUA) annual meeting. To learn more please visit: https://suoctc.org/about/links/suo-ctc-cg-oncology-nmibc-fellowship.aspx

About Bladder Cancer
More than 83,000 people are estimated to be diagnosed with bladder cancer in 2024. NMIBC is the most common form of bladder cancer, representing approximately 75% of newly diagnosed cases. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three quarters of newly diagnosed cases.

About The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)
SUO-CTC is a clinical research investigator network of over 600 members from more than 300 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO). To learn more please visit: https://suoctc.org/

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts
SUO-CTC:
Pam Murphy
Executive Director, Clinical Research Services
pam@wjweiser.com

CG Oncology:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com

FAQ

What is the CG‑SUO‑CTC NMIBC Research Fellowship announced on December 18, 2025 by CG Oncology (CGON)?

It is the second annual fellowship awarding research grants to support investigators studying Non‑Muscle Invasive Bladder Cancer.

How much funding does each CG‑SUO‑CTC NMIBC fellowship provide for CGON applicants?

Two applicants will each receive a grant of $50,000.

What is the application deadline for the CGON and SUO‑CTC NMIBC fellowship?

Applications are due February 27, 2026 by 5:00 PM U.S. Eastern Time.

Who is eligible to apply for the CG‑SUO‑CTC NMIBC Research Fellowship (CGON)?

Investigators in basic, translational, or clinical NMIBC research working in environments that can support transformational studies are eligible.

Where must award recipients present their completed CGON‑funded NMIBC project?

The completed project must be presented at the SUO meeting at the American Urological Association annual meeting.

How are applications evaluated for the CG‑SUO‑CTC NMIBC fellowship from CGON?

Applications are evaluated on the quality of the proposed research plan and the applicant’s available resources and research environment.